Paul Farrington
Impact in
-
- PARP inhibition in cancer therapy
- Cancer Immunotherapy and Biomarkers
-
- Immunotherapy and Immune Responses
- interferon and immune responses
- Immune Cell Function and Interaction
Papers in
- Oncology 3
- Cancer Immunotherapy and Biomarkers 2
- HER2/EGFR in Cancer Research 1
-
- Monoclonal and Polyclonal Antibodies Research 1
- Advances in Oncology and Radiotherapy 1
- Co-authors
- Tim Illidge (1 shared paper)Viia Valge-Archer (1 shared paper)Ankur Karmokar (1 shared paper)Barry R. Davies (1 shared paper)Kyoko Nakamura (1 shared paper)Elaine Cadogan (2 shared papers)Gareth Hughes (1 shared paper)Simon J. Dovedi (1 shared paper)
- Journals
- Clinical Cancer Research (1 paper)CPT Pharmacometrics & Systems Pharmacology (1 paper)Cancer Research (1 paper)Journal of Pharmacology and Experimental Therapeutics (1 paper)
- Partner nations
- United KingdomSingapore
In The Last Decade
Paul Farrington
4 papers receiving 53 citations
Peers
Comparison fields: 5 of 19
- Oncology 28
- Immunology 14
- Cancer Research 6
- Molecular Biology 27
- Genetics 2
Countries citing papers authored by Paul Farrington
This map shows the geographic impact of Paul Farrington's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Paul Farrington with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Paul Farrington more than expected).
Fields of papers citing papers by Paul Farrington
This network shows the impact of papers produced by Paul Farrington. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Paul Farrington. The network helps show where Paul Farrington may publish in the future.
Co-authors
The 25 scholars most cited alongside Paul Farrington, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2021 | 45 | |
| 2 | 2023 | 5 | |
| 3 | 2023 | 2 | |
| 4 | Examining inhibition of VEGFR and EGFR signaling in MMTV-neu transgenic mice with well-established tumors: an immunohistochemical and oncogenomic analysis of AZD2171, vandetanib and gefitinib treatment | 2007 | 1 |
About Paul Farrington
Paul Farrington is a scholar working on Oncology, Radiology, Nuclear Medicine and Imaging, Surgery, Molecular Biology and Pulmonary and Respiratory Medicine, having authored 4 papers that have together received 53 indexed citations. Recurring topics across this work include Cancer Immunotherapy and Biomarkers (2 papers), Angiogenesis and VEGF in Cancer (1 paper), Radiation Therapy and Dosimetry (1 paper), Immunotherapy and Immune Responses (1 paper), Monoclonal and Polyclonal Antibodies Research (1 paper), HER2/EGFR in Cancer Research (1 paper), Advances in Oncology and Radiotherapy (1 paper) and Bladder and Urothelial Cancer Treatments (1 paper). The work is most often cited by research in Oncology (28 citations), Immunology (14 citations), Cancer Research (6 citations), Molecular Biology (27 citations) and Genetics (2 citations). Paul Farrington has collaborated with scholars based in United Kingdom and Singapore. Frequent co-authors include Tim Illidge, Viia Valge-Archer, Ankur Karmokar, Barry R. Davies, Kyoko Nakamura, Elaine Cadogan, Gareth Hughes, Simon J. Dovedi, Neil H. James and Antonio Ramos‐Montoya. Their work appears in journals such as Clinical Cancer Research, CPT Pharmacometrics & Systems Pharmacology, Cancer Research and Journal of Pharmacology and Experimental Therapeutics.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.